secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2024-01-19T23:59:59+00:00
Accession:  0001628280-24-001784
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo Therapeutics eliminates 2023 executive bonuses, adopts retention program amid capital raise
--------------------------------------------------------------------------------

- Board determined not to award 2023 annual cash bonus to CEO Sandy Macrae or CFO Prathyusha Duraibabu.
- Retention program approved for US/UK employees; CEO eligible for up to $429,820, CFO up to $193,584.
- Retention payments conditioned on achieving capital-raising milestones by end of 2024 or change of control.
- Executives must remain employed through payment date; program highlights company's cash needs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024001784/0001628280-24-001784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024001784/sgmo-20240119.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-001784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer